Okok_老虎社区_美港股上老虎

Jimmy365
2022-02-02

Okok

GSK to get $1.25 bln to settle HIV drug patent row with Gilead

Feb 2 (Reuters) - Britain's GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as

GSK to get $1.25 bln to settle HIV drug patent row with Gilead

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":633327448,"tweetId":"633327448","gmtCreate":1643793567147,"gmtModify":1643793567436,"author":{"id":3562019478826489,"idStr":"3562019478826489","authorId":3562019478826489,"authorIdStr":"3562019478826489","name":"Jimmy365","avatar":"https://static.tigerbbs.com/f0b5ef01e17ff83b62385dd919d36027","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Okok</p></body></html>","htmlText":"<html><head></head><body><p>Okok</p></body></html>","text":"Okok","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/633327448","repostId":2208235710,"repostType":4,"repost":{"id":"2208235710","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1643790588,"share":"https://www.laohu8.com/m/news/2208235710?lang=&edition=full","pubTime":"2022-02-02 16:29","market":"us","language":"en","title":"GSK to get $1.25 bln to settle HIV drug patent row with Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2208235710","media":"Reuters","summary":"Feb 2 (Reuters) - Britain's GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as","content":"<html><head></head><body><p>Feb 2 (Reuters) - Britain&#39;s GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.</p><p>The settlement, announced by GSK on Tuesday, relates to Gilead&#39;s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare&#39;s dolutegravir and other similar compounds.</p><p>HIV medicines developed by ViiV, in which Pfizer    and Japan&#39;s Shionogi    also hold small stakes, are a major part of GSK&#39;s plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.</p><p>The payment is expected to be made in the first quarter this year, London-listed GSK said</p><p>Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.</p><p>The settlement weighed on Gilead&#39;s fourth-quarter results on Tuesday as its profit missed market expectations.</p><p>Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.</p><p>Gilead&#39;s Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK&#39;s ViiV and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Gilead&#39;s top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.</p><p>Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.</p><p>While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.</p><p>On Tuesday, U.S. regulators expanded the use of ViiV&#39;s Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK to get $1.25 bln to settle HIV drug patent row with Gilead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK to get $1.25 bln to settle HIV drug patent row with Gilead\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-02-02 16:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Feb 2 (Reuters) - Britain&#39;s GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.</p><p>The settlement, announced by GSK on Tuesday, relates to Gilead&#39;s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare&#39;s dolutegravir and other similar compounds.</p><p>HIV medicines developed by ViiV, in which Pfizer    and Japan&#39;s Shionogi    also hold small stakes, are a major part of GSK&#39;s plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.</p><p>The payment is expected to be made in the first quarter this year, London-listed GSK said</p><p>Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.</p><p>The settlement weighed on Gilead&#39;s fourth-quarter results on Tuesday as its profit missed market expectations.</p><p>Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.</p><p>Gilead&#39;s Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK&#39;s ViiV and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Gilead&#39;s top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.</p><p>Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.</p><p>While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.</p><p>On Tuesday, U.S. regulators expanded the use of ViiV&#39;s Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","GSK":"葛兰素史克","BK4007":"制药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208235710","content_text":"Feb 2 (Reuters) - Britain's GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.The settlement, announced by GSK on Tuesday, relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.HIV medicines developed by ViiV, in which Pfizer    and Japan's Shionogi    also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.The payment is expected to be made in the first quarter this year, London-listed GSK saidGilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.The settlement weighed on Gilead's fourth-quarter results on Tuesday as its profit missed market expectations.Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.Gilead's Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK's ViiV and is one of Gilead's top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.On Tuesday, U.S. regulators expanded the use of ViiV's Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":770,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

GSK to get $1.25 bln to settle HIV drug patent row with Gilead

评论（1）

热议股票